ANI Pharmaceuticals, Inc. (ANIP) Earnings

Management highlights

- Strategic Transformation & Overall Performance * The company is executing on its transformation from a diversified pharma business to a leading rare disease company, with strong Q2 2026 results that exceeded prior expectations. * Record total revenues and adjusted EBITDA were achieved while completing the largest rare disease sales force expansion in company history, increasing sales headcount by 50% to ~180 representatives, focused on the new gout indication for Cortofan Gel. * The company's virtuous cycle model uses cash flow from generics and existing brands to fund rare disease growth. - Rare Disease Branded Portfolio Updates * Cortofan Gel: Momentum in existing core specialties (rheumatology, nephrology, neurology, ophthalmology, pulmonology) continued into Q3 2026, with July posting the highest number of new patient cases initiated on record. Ophthalmology volumes doubled year-over-year for the second consecutive quarter. The gout-focused sales expansion was fully operational by the end of June 2026 as planned, with early leading indicators showing strong demand: over 95% of new gout sales representatives have initiated multiple new patient cases, over one-third of new prescribers have initiated two or more cases, and demand is balanced across primary care and podiatry settings. The overall ACTH market is expected to grow nearly 30% in 2026 to over $1.3 billion, with Cortofan Gel vastly underpenetrated across a total addressable population of almost 1 million patients. * Alluvion: Top-line results from the Phase 4 open-label Synchronicity trial in noninfectious uveitis of the posterior segment (NIUPS) have been released, with detailed data to be presented at a medical conference in Q4 2026. The long-term addressable patient opportunity for Alluvion in DME and NIUPS is estimated to be at least 10x the current treated patient population. - Generics Business Updates * 12 generic launches have been completed in 2026 year-to-date, and the company remains on track to launch at least 15 generics in full-year 2026. ANI maintains its position as the number two player in overall CGT filings. * Approximately 95% of the company's revenues come from finished goods manufactured in the U.S., positioning it well to capitalize on evolving tariff and supply chain landscape opportunities. - Capital Allocation * The company deploys a high single-digit percentage of generics revenue into generic R&D programs, while continuing to invest in organic rare disease growth. A disciplined approach is maintained, with a healthy balance sheet that provides capacity for inorganic growth opportunities to expand the rare disease business.

Guidance

- Full-year 2026 total company net revenue guidance is maintained at $1.08 billion to $1.14 billion, representing 26% year-over-year growth at the midpoint, with rare disease expected to represent approximately 60% of total 2026 revenue. - Cortofan Gel full-year 2026 net revenue guidance is modestly revised upward to $520 million to $540 million, from the prior range, to reflect actual first-half 2026 results; back-half expectations remain largely unchanged from the start of the year, and this guidance still represents 50% to 55% year-over-year growth for 2026. Q3 2026 Cortofan revenue is expected to be $143 million to $153 million, with further sequential growth in Q4 2026. - Alluvion full-year 2026 net revenue guidance is reaffirmed at $78 million to $83 million, with stronger revenue expected in the second half of the year compared to the first half, and assumes no meaningful contribution from third-party patient assistance foundations consistent with prior expectations. - Full-year 2026 adjusted non-GAAP EBITDA guidance is reaffirmed at $285 million to $300 million, representing 27% year-over-year growth. Q3 2026 adjusted EBITDA is expected to be lower sequentially than Q2 2026 (but higher than Q1 2026) due to the lower development milestone revenue from the Harmony deal and the first full quarter of gout expansion operating expenses; Q4 2026 EBITDA is expected to be the highest of the year as revenue growth from the expansion begins to drive operating leverage. - Full-year 2026 adjusted non-GAAP diluted EPS guidance is reaffirmed at $9.19 to $9.69, adjusted gross margin guidance is maintained at 59.9% to 60.9%, and the GAAP effective tax rate expectation of 26% to 28% is unchanged. - The remaining $2 million development milestone revenue from the Harmony outlicensing deal is expected to be recognized in Q3 2026. - Operating leverage from the 2026 50% sales force expansion is expected to be realized in 2027 and beyond.

Segment performance

Total company net revenues for Q2 2026 were $266 million, a 26% year-over-year increase. Breakdown by segment: 1) Cortofan Gel (rare disease branded): $117.1 million in net revenues, up 43% year-over-year and 56% quarter-over-quarter from Q1 2026, contributing ~44% of total Q2 revenue. 2) Alluvion (rare disease branded): $18.7 million in net revenues, down 16% year-over-year due to timing of international shipments, contributing ~7% of total Q2 revenue. 3) Generics: $99.1 million in net revenues, up 10% year-over-year, contributing ~37% of total Q2 revenue. 4) Harmony Intellectual Property Outlicensing: $17.7 million in recognized revenue (consisting of $9.7 million in royalty income and $8 million in development milestone revenue), contributing ~7% of total Q2 revenue. Adjusted non-GAAP EBITDA for the quarter was a record $71.6 million, up 32% year-over-year.

Risks & headwinds

- Forward-looking statements related to revenue growth, demand ramp for the gout expansion, and market penetration are subject to substantial inherent risks and uncertainties, and the company undertakes no obligation to update these statements. - Third-party market data (such as IQVIA data) has historically had quarterly volatility and can over or understate actual results, creating potential disconnect between public third-party data and the company's actual performance. - While the company reports strong early leading indicators for the gout expansion, the product is still vastly underpenetrated and the long-term adoption trajectory across primary care and podiatry is still emerging. - Reimbursement and prior authorization processes can create timing lags for revenue recognition, and payers may implement new access restrictions like step edits that could impact patient access and demand. - The company's M&A pipeline of rare disease acquisition targets carries inherent execution and integration risk, and there is no guarantee that attractive opportunities will be identified or completed on favorable terms.

Analyst Q&A

• Q: What has early uptake of Cortofan in the new gout indication looked like, and what drives the expected step-up in Cortofan revenue in Q4? What is the current penetration of Cortofan across its total addressable market? /

  A: The gout sales expansion was fully operational by the end of June 2026, with very positive early leading indicators: over 95% of new reps have generated multiple new patient cases, over one-third of new prescribers have initiated two or more cases, and demand is balanced across primary care and podiatry. The expansion increased total sales reps by 50% from 120 to 180, 3x larger than the 2025 expansion. Q3 will build momentum, so Q4 will see a significantly larger impact from the full deployment of the gout expansion, alongside continued momentum from existing specialties that hit a record for new cases in July, and typical Q4 channel and insurance tailwinds. Penetration across the total addressable market remains very low, leaving a large multi-year growth opportunity.

• Q: Why did you modestly revise full-year Cortofan guidance lower, and what is the current status of prior authorization issues that impacted Q1? Are there ongoing access headwinds impacting performance? /

  A: Insurance re-verification issues that impacted Q1 2026 are fully behind the company, with no impact on Q2 results. The modest guidance revision solely reflects actual reported results from the first half of 2026; expectations for the back half of the year remain largely unchanged from the start of the year. No new incremental access headwinds or step edits have impacted the business, and the gout expansion is tracking ahead of internal demand metrics.

• Q: What does "new cases initiated" mean, how long does it take to fill a prescription after a case is initiated, and when will the sales force expansion drive meaningful operating leverage? Will additional expansion be needed? /

  A: "New cases initiated" is equivalent to new prescriptions/enrollment forms. Time from initiation to fulfillment varies from a few days to weeks based on payer, patient, and provider factors, but the company has refined this process over 5 years of launch and there are no new lags or headwinds. The 50% sales force expansion completed in 2026 will deliver full operating leverage starting in 2027, as 2026 bears the full cost of the expansion while revenue ramps. No additional large-scale expansion is planned in the near term after this year's large increase.

• Q: What is your current approach to M&A for rare disease, and what types of assets are you targeting? /

  A: Disciplined M&A to expand the scope and scale of the rare disease business is a top capital allocation priority. The company is primarily evaluating commercial or near-commercial assets that can leverage existing capabilities: either synergy with existing prescriber call points, or utilization of ANI's existing infrastructure including market access, medical affairs, and patient support, which are critical capabilities in the rare disease space.